While ICI have revolutionized the treatment of non-small cell lung cancer (NSCLC), prior studies indicate limited benefit in patients with EGFR-mutant lung adenocarcinoma [9–12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.